Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
This article was originally published in The Pink Sheet Daily
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
You may also be interested in...
CEO Olivier Brandicourt's multi-pronged strategy involves defending in core areas like diabetes, vaccines and rare diseases, building in consumer healthcare, oncology and multiple sclerosis and reviewing strategic alternatives in other areas, including animal health.
Bevy of new products like Novo Nordisk’s Tresiba offer some incremental improvements over older insulins, but in an increasingly crowded market, payers have the upper hand.
Sanofi’s next-generation long-acting insulin will compete against an entrenched rival, the company’s own Lantus – a challenging proposition for any drug marketer, especially in the increasingly cost-conscious diabetes sector.